Drug Makers’ Shares Hit ‘All-Time High’ Off Of Price-Gouging American Patients Today Big Pharma giant Novartis announced better-than-expected earnings for the second quarter of 2019. The brand name drug maker reported $11.76 billion in sales in Q2 – up from $11.34 billion last year – beating analysts’ expectations. As a result, the company raised…
Drug Maker Bests Q2 Forecasts After Hiking Prices on Dozens of Drugs in 2019 It’s that time again. Pharmaceutical companies are starting to report their earnings for Q2. Big Pharma giant Johnson…
Greater List Price Transparency Will Help Hold Big Pharma Accountable, Deter Price-Gouging For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.C. – The…
Drug Makers Continue Price-Gouging Patients as Americans Demand Accountability The summer is heating up and so too is Big Pharma’s zeal for putting profits over people. Brand name drug makers…
America’s seniors and taxpayers received a huge win today when the administration made the right call to withdraw a proposal, known as the Rebate Rule, from the Department of Health and Human…
Decision to Sideline Misguided Proposal a Huge Win for America’s Seniors & Taxpayers, Loss for Big Pharma For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington…
Proposed Bill Would Undermine Fair and Efficient Review Process For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.C. – The Campaign for Sustainable Rx…
Lauren Aronson The Hill July 9, 2019 The American people are demanding that Congress hold Big Pharma accountable and the momentum to lower prescription drug prices has never been greater. For years…
Senators Advance Three Measures to Help Lower Drug Prices as Momentum to Hold Drug Makers Accountable Builds For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.
Advancement of CREATES and FAIR Drug Pricing Acts Marks Step Toward Boosting Competition and Transparency For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.C.